Research programme: oral antithrombotic agents - GLYCODesign
Alternative Names: Oral antithrombotic agents research programme - GLYCODesignLatest Information Update: 22 Aug 2002
At a glance
- Originator GLYCODesign
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Thrombosis
Most Recent Events
- 22 Aug 2002 Discontinued - Preclinical for Cardiovascular disorders in Canada (PO)
- 22 Aug 2002 Discontinued - Preclinical for Thrombosis in Canada (PO)
- 13 Sep 2000 Preclinical development for Cardiovascular disorders in Canada (PO)